XOMA - ゾ―マ （XOMA Corporation） ゾ―マXOMAのチャート
XOMAの企業情報
| symbol | XOMA |
|---|---|
| 会社名 | XOMA Corp （ゾ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エックス・オー・エム・エー（XOMA Corporation）は抗体ベースの治療薬の発見と開発に従事する会社。同社における主要な薬品候補はGevokizumab（旧名：XOMA 052）であり、炎症性サイトカインであるインターロイキン-1β（IL-1 beta）を阻害するように設計されたヒト化モノクローナル・アロステリック調節抗体である。同社の前臨床パイプラインは、「XMet」と名付ける生体内でインスリン受容体を活性化または感作する抗体のクラスを含み、インスリンの関与を持つ複数の疾患および糖尿病を治療する潜在的な新規治療法を代表する。平成24年1月17日、同社はServierから降圧剤製品ポートフォリオに係る特定の米国内の権利を取得したことを発表した。同製品ポートフォリオは市販されたアンギオテンシン変換酵素（ACE）阻害剤であるACEON（ペリンドプリルerbumine）、並びに一種のペリンドプリル（ペリンドプリル・アルギニン）を他の活性成分と組み合わされた３種類の固定用量の組み合わせ（FDC）の製品候補を含む。 ゾ―マは米国のバイオ医薬品メ―カ―。アロステリック調節作用を持つ抗体ベ―スの治療薬を開発、製造する。遺伝子操作たんぱく質、ペプチド、抗体薬などがある。バクテリアや真菌類による感染症、感染合併症、炎症性障害などの研究に焦点を置く。本社はカリフォルニア州バ―クレ―。 XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA's pioneering efforts in the discovery and development of antibody therapeutics. The Company's royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. |
| 本社所在地 | 2910 Seventh Street Berkeley CA 94710 USA |
| 代表者氏名 | W. Denman Van Ness W.デンマン・ヴァン・ネース |
| 代表者役職名 | Lead Independent Chairman of the Board |
| 電話番号 | +1 510-204-7239 |
| 設立年月日 | 29618 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1986年 |
| 従業員数 | 86人 |
| url | www.xoma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/xoma |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 19.02500 |
| 終値（lastsale） | 16.46 |
| 時価総額（marketcap） | 138052702.98 |
| 時価総額 | 時価総額（百万ドル） 131.76230 |
| 売上高 | 売上高（百万ドル） 44.25800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 107.92530 |
| 当期純利益 | 当期純利益（百万ドル） 9.39000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 XOMA Corp revenues decreased 76% to $2.7M. Net loss applicable to common stockholders decreased 39% to $5.8M. Revenues reflect Revenue from contracts with customers decrease of 75% to $2.7M Revenue recognized under units-of-revenu decrease from $225K to -$24K. Lower net loss reflects Other Research_Development decrease of 90% to $609K (expense) Restructuring decrease of 87% to $459K (expense). |
XOMAのテクニカル分析
XOMAのニュース
XOMA Buys Royalty, Milestone Interest In Checkmate''s Vidutolimod From Kuros Biosciences 2021/07/15 10:38:46 Benzinga
XOMA Corporation (NASDAQ: XOMA ) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc''s (NASDAQ: CMPI ) vidutolimod (CMP-001), for $7.0 million upfront plus $166.5 million as sales milestones . Checkmate currently is enrolling patients in a Full story available on Benzinga.com
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuross license agreement with Checkmate Pharmaceuticals 2021/07/15 08:17:00 Intrado Digital Media
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules
XOMA Acquires Royalty and Milestone Interest in Checkmates Vidutolimod (CMP-001) from Kuros Biosciences 2021/07/15 08:00:00 Intrado Digital Media
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones. Vidutolimod is designed to trigger the bodys innate immune system to attack tumors in combination with other therapies. The U.S. Food and Drug Administration has granted Fast Track designation to vidutolimod for the treatment of certain types of metastatic or unresectable melanoma and an Orphan Drug designation for Stages IIb - IV melanoma.
EQS-Adhoc: Kuros Biosciences AG: Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros''s license agreement with Checkmate Pharmaceuticals 2021/07/15 05:04:00 FinanzNachrichten
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with X
XOMA Corp - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th declares $0.5583 dividend 2021/06/21 12:27:23 Seeking Alpha
NEXE Innovations says its Xoma Superfoods product line now available on Amazon in US and Canada 2021/06/03 13:55:00 Proactive Investors
NEXE Innovations Inc (CVE:NEXE) (OTCMKTS:NEXNF) (FRA:NX5) announced that its popular Xoma Superfoods product line is now available on both Amazon.com and Amazon.ca e-commerce marketplaces in the US and Canada. NEXE is delighted with the Amazon affiliation," said CEO Darren Footz in a statement. "Amazon is the largest e-commerce platform in the world, and will allow us to greatly expand our sales, brand presence and market reach. We are excited about the sales exposure that our listing on Amazon''s Grocery and Gourmet Food section will bring to our XOMA line." READ: NEXE Innovations signs commercial relationship with online vegan marketplace operator, Vejii Holdings; names new CFO As previously announced in April, NEXE has engaged Orca Pacific, a full-service marketing agency specializing in Amazon sales strategies. Orca Pacific is an organization comprised of former Amazonians and top retail industry experts that use a combination of know-how and machine learning software to develop and implement custom Amazon strategies to drive sustainable top-line growth.
NEXE Innovations signs commercial relationship with online vegan marketplace operator, Vejii Holdings; names new CFO 2021/05/27 14:45:00 Proactive Investors Canada
NEXE Innovations Inc. (CVE:NEXE) (OTCMKTS:NEXNF) (FRA:NX5) said it has signed a commercial relationship with Vejii Holdings Ltd., with the intent to sell NEXE''s XOMA Superfoods line on Vejii''s e-commerce marketplace - https://shopvejii.com/brand/xoma/ - in the US. Xoma Superfoods is NEXE''s in-house superfoods brand featuring NEXE''s single-serve, fully compostable, plant-based beverage pods, compatible with Keurig''s single-serve brewing systems. Vejii operates the largest online vegan marketplace in the US and provides its customers with access to thousands of vegan and plant-based products in one place. READ: NEXE Innovation and Rritual to collaborate on new superfoods products in NEXE compostable pods "NEXE is proud to announce that our flagship XOMA Superfoods line will soon be available on Vejii''s marketplace," Darren Footz, CEO of NEXE said in a statement. "Partnering with Vejii is an exciting milestone for NEXE as we expand our distribution network for our popular XOMA product line.